Dashboard
Healthy long term growth as Net Sales has grown by an annual rate of 12.34%
Positive results in Jun 25
With ROE of 11.90%, it has a attractive valuation with a 2.75 Price to Book Value
Company is among the highest 1% of companies rated by MarketsMojo across all 4,000 stocks
Consistent Returns over the last 3 years
Stock DNA
Pharmaceuticals & Biotechnology
SEK 121,306 Million (Large Cap)
23.00
NA
0.00%
0.34
19.23%
3.37
Total Returns (Price + Dividend) 
Swedish Orphan Biovitrum AB for the last several years.
Risk Adjusted Returns v/s 
News

Swedish Orphan Biovitrum AB Reports Significant Profit Growth Amid Financial Reevaluation
Swedish Orphan Biovitrum AB has recently adjusted its evaluation, reflecting significant changes in its financial metrics and market position. The company reported strong quarterly results, with notable increases in pre-tax and net profits, alongside a solid debt-equity ratio, indicating a robust financial foundation within the Pharmaceuticals & Biotechnology sector.
Read More Announcements 
Corporate Actions 
Quality key factors 
Valuation key factors
Technicals key factors
Shareholding Snapshot : Mar 2024
Shareholding Compare (%holding) 
Foreign Institutions
Held in 0 Schemes (0%)
Held by 1 Foreign Institutions (0.0%)
Quarterly Results Snapshot (Consolidated) - Jun'25 - YoY
YoY Growth in quarter ended Jun 2025 is 13.47% vs 11.70% in Jun 2024
YoY Growth in quarter ended Jun 2025 is 183.04% vs 0.90% in Jun 2024
Annual Results Snapshot (Consolidated) - Dec'24
YoY Growth in year ended Dec 2024 is 17.64% vs 17.74% in Dec 2023
YoY Growth in year ended Dec 2024 is 61.02% vs -8.68% in Dec 2023






